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show an increase in cardiovascular events on celecoxib versus
placebo nor celecoxib versus other nonselective NSAIDs (6) . One
would have to conclude, then, that there are no clinical outcome
data that support the hypothesis and statement of Bing and
Lomnicka (1) that the COX-2 inhibitor celecoxib causes cardio-
vascular events.
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REPLY
White, in his response to our study “Cyclooxygenase (COX-2)
Inhibitors and Cardiovascular Thromboembolic Events,” stated
“there are no clinical outcome data that support the hypothesis and
statement of Bing and Lomnicka that the COX-2 inhibitor
celecoxib causes cardiovascular events.” We have indeed no clinical
material of our own that demonstrates the effect of this selective
nonsteroidal anti-inflammatory compound (NSAID) on cardiac
events. But it was not our purpose to cite clinical material of our
own in support of the effects of celecoxib. Rather, we attempted to
demonstrate an experimental basis for the clinical trials by
Mukherjee et al. (1). We primarily wanted to stress the importance
of changes in prostanoids in heart muscle, specifically of throm-
boxane and prostacyclin. Prostacyclin is a vasodilator that prevents
cardiac arrhythmias and platelet aggregation; thromboxane, in
contrast, acts as a vasoconstrictor initiating ventricular arrhythmias
(2). Therefore, in the heart a decline in prostacyclin results in
coronary vasoconstriction, as does an increase in thromboxane. In
the kidney, a disproportionate decline in prostacyclin has even
more dire consequences (3), because both nonselective and selec-
tive NSAIDs cause acute renal failure (4–6). Changes in prosta-
noids in heart and kidney are related to the activity of cyclooxy-
genases (COX), which catalyze the conversion of arachidonic acid.
It was not our intention to present clinical evidence about the
effect of celecoxib. Rather, we wanted to stress reasons for the
possible relationship of NSAIDs to cardiac events. The decline in
prostacyclin following administration of NSAIDs and the resulting
deterioration in function confirm the predominant role of prosta-
noids in organ function.
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